Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Anika Therapeutics has entered into a new agreement with Medline Industries to commercialize the company's advanced wound care product 'Hyalomatrix', in the US on an exclusive basis through 2019.
Subscribe to our email newsletter
Under the deal, Anika will receive product payment and royalty revenues from the sale of the product by Medline.
Hyalomatrix is a biologically-derived matrix for in-growing cells, and has the US Food and Drug Administration (FDA) marketing clearance.
Medline is a manufacturer and distributor of healthcare products and services in the US, and has over 1,200 dedicated sales representatives to support its broad product line.
Anika Therapeutics president and CEO Charles Sherwood said the commercialization of Hyalomatrix by Medline in the US is an important milestone achievement in the company’s efforts to expand its advanced wound care product franchise.
"We have been focused on expanding our marketing footprint of Hyalomatrix in Europe and building our Hyalomatrix distribution network in South America," Sherwood said.
"We are enthusiastic to have a strategic partner with a strong reputation in wound care and complementary products launching Hyalomatrix in this significant geographic market."